Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Sharck Soup -- Ignore unavailable to you. Want to Upgrade?

To: Sharck who wrote (37709)	5/16/2002 2:47:08 AM
From: nokomis	Respond to of 37746

Gotta say I'm disappointed in you..but then, you're your own man (or are you?)

To: Sharck who wrote (37709)	5/18/2002 10:31:37 AM
From: Victor Lazlo	Respond to of 37746

Sharckie, here's a good read on the bio sector, and the FDA's caution of late. You da man, dude! The panel will meet Thursday, and by day's end, it will recommend to the FDA whether to approve Amevive. The decision is crucial to Biogen, which badly needs a new revenue stream to compensate for flattening sales of its huge-selling multiple sclerosis drug, Avonex. And in a year rife with setbacks and failures, the decision is also critical to the biotech industry. Industry observers say the FDA has become increasingly cautious in approving new drugs, repeatedly asking companies for additional information, delaying their approval, or keeping them off the market altogether. The setbacks, coupled with disappointing clinical trial results, have driven investors from the biotech sector. digitalmass.boston.com